Showing 7411-7420 of 8832 results for "".
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- New Government Advisory Cites Risk for Ransomware Attacks on Healthcare Systemhttps://practicaldermatology.com/news/new-government-advisory-cites-risk-for-ransomware-attacks-on-healthcare-system/2460587/A new advisory coauthored by the Cybersecurity and Infrastructure Security Agency (CISA), the Federal Bureau of Investigation (FBI), and the Department of Health and Human Services (HHS) warns of the potential for ransomware attacks against hospitals and medical systems. “CI
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they
- Exclusive: Global Report Identifies Strategies for Improved Quality of Care in ADhttps://practicaldermatology.com/news/exclusive-global-report-identifies-strategies-for-improved-quality-of-care-in-ad/2460585/Gathering and synthesizing data from in-person visits from 32 care centers in 17 countries around the world, the “Improving Quality of Care in AD” report offers clear recommendations to improve care and help patients better manage atopic dermatitis.Commissioned and funded by Sano
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- Beiersdorf Inc. Observes 10 Years of dermMentors Residents of Distinctionhttps://practicaldermatology.com/news/beiersdorf-inc-observes-10-years-of-dermmentors-residents-of-distinction/2460577/As part of the dermMentors™ Resident of Distinction Award™, Beiersdorf Inc. sponsored five top dermatology residents to attend the 16th Annual Coastal Dermatology Symposium, held in a Virtual Format for 2020. The 2020 Residents of Distinction are Shaundra Eichsta
- Label Update for Enstilar Foam Highlights Long-Term Use in Adultshttps://practicaldermatology.com/news/label-update-for-enstilar-foam-highlights-long-term-use-in-adults/2460575/The US Prescribing Information (USPI) for Enstilar® (calcipotriene and betamethasone dipropionate) Foam from LEO Pharma A/S now includes data on long-term use in adults with plaque psoriasis. The update results from the FDA approving a supplemental New Drug Application (sNDA).
- Industry Responds to COVID-19: TrueHero Face Shieldshttps://practicaldermatology.com/news/truehero-face-shields-offer-reusable-medical-grade-protection/2460572/Responding to the need for PPE across the US, Jamestown Plastics, has pivoted production to manufacture face shields to protect from COVID-19. The TrueHero Extreme Coverage Shield is suitable for medical use, including in dermatology and aesthetic practices.
- New from BTL: Emsculpt NEO Launcheshttps://practicaldermatology.com/news/new-from-btl-emsculpt-neo-launches/2460571/The first procedure to combine radio frequency heating and high-intensity focused electromagnetic waves into a single therapy, Emsculpt NEO from BTL, has launched. It is FDA-cleared to eliminate fat cells non-invasively. Emsc